key: cord-0799306-bljvvhxf authors: Terruzzi, Ileana; Senesi, Pamela title: Does intestinal dysbiosis contribute to an aberrant inflammatory response to SARS-CoV-2 in frail patients? date: 2020-09-01 journal: Nutrition DOI: 10.1016/j.nut.2020.110996 sha: 0a2a2de05a427fb499133d6c9850fd95d648e454 doc_id: 799306 cord_uid: bljvvhxf In few months, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become the main health worldwide problem. Epidemiological studies revealed that population has different vulnerability to SARS-CoV-2: severe outcome of COVID-19, with an increased risk of death, is observed in patients with metabolic syndrome, diabetic and heart conditions (frail population). Excessive pro-inflammatory cytokine storm could be the main cause of enlarged vulnerability in frail population. In subjects with diabetes and/or heart disease, a low inflammatory state is often associated with gut dysbiosis. The increase of microbial metabolites (i.e. TMAO and LPS), generating an inflammatory microenvironment is probably associated with an improved risk of severe illness from COVID-19. Nutritional interventions aimed at restoring gut microbial balance could represent preventive strategies to protect frail population from COVID-19. This narrative review presents the possible molecular mechanisms by which intestinal dysbiosis, enhancing inflammatory state, could promote SARS-CoV-2 spreading infection. Some nutritional strategies to counteract inflammation state in frail patients are also analysed. Epidemiological studies indicate that the elderly and above all subjects affected by metabolic syndrome, diabetes and/or cardiovascular diseases (especially hypertension) are more susceptible to SARS-CoV-2 infection as highlighting from an increased symptoms severity, disease rate progression and lastly mortality [2,5]. Given the high number of infected people who need intensive care and the ineffectiveness/aspecificity of current adopted therapies, many countries are now committed to limiting SARS-CoV-2 exponential growth of making extraordinary decisions, including the 'lock-down' of some regions or entire countries with a severe economic impact [6]. Hoping to contain COVID-19 pandemic as soon as possible and until vaccine development, the problem of higher SARS-CoV-2-associated risk and mortality in frail subpopulation, (diabetics and subjects with metabolic syndrome or cardiovascular diseases) remains. Some authors have strongly advised to implement blood glucose management in diabetic patients, using online service and avoiding person-to-person contact [7]. Others have suggested a tighter nutritional control to avoid malnutrition conditions [8]. 4 However, to protect frail subjects, it is necessary to investigate the mechanisms involved in the aberrant immune response triggered by SARS-Cov-2 and to identify possible therapeutic targets to counteract it. SARS-CoV-2 activates intracellular stress pathways, inducing and taking advantage of aberrant response by host innate and adaptive immune system, which plays a crucial role in causing fatal pneumonia and death [1]. SARS-CoV-2, as SARS-CoV, enters the host target cells by binding to ACE2 Inflammatory process begins after the interaction of SARS-CoV-2 with toll-like receptor (TLR), whose activation triggers a sequence of responses from the host cell, leads to NF-kB activation through the dissociation of its inhibitor (Figure 1 ). axis alteration worsens the inflammation state and multi-organ damages ( Figure 1 ). During the first weeks of pandemic, some authors and social media have speculated that ACE inhibitors and AngII type 1 (AT1) receptor blockers (ARBs), used for treatment of hypertension, facilitates SARS-CoV-2 infection by increasing ACE2 expression. The data, supporting this hypothesis, are conflicting. Although ACE and ACE2 enzymes are highly homologous, they catalyse different reaction of the renin-angiotensin system and ACE inhibitors are not able to inhibit ACE2. Moreover, different works reported that ARBs increase ACE2 expression, but ARBs action is dose-related and tissue-specific. Inappropriate information about these antihypertensives caused stress and anxiety in patients and some of them have discontinued treatment, probably aggravating their condition. Currently, ACE inhibitors or ARBs correlation with SARS-CoV-2 severe illness is not clinically proven. Indeed, as mentioned above, elevated Ang-(1-7) probably has a protective pulmonary action. For this reason, therapy with renin-angiotensin system blockers should not be withdrawn and should not be modified to prevent SARS-CoV-2 infection [43 -44] . . Intestinal dysbiosis could contribute to the aberrant inflammatory response triggered by Alternatively, the use of prebiotics and probiotics could be convenient to decrease TMAO production. Overall, clinical data exists that patients with obesity, hypertension, diabetes and in general with metabolic syndrome (frail patients) are at higher risk for COVID-19. As known, the interconnection between these pathologies and gut microbiota composition promotes an aberrant secretion of bacterial products, including TMAO and LPS. LPS binding to TRL4 induced a low-grade inflammation state. Data reported in literature suggested how SARS-CoV-2 interacting with TRL activates NLRP3 inflammasome, that can also be activated by TMAO (Figure 1) , worsening the host cellular pro-inflammatory microenvironment. Pending the development of specific drugs or vaccine, effective strategies to ensure good health for patients with metabolic syndrome must be identified. It is well established that modulation of the microbiome through diet or probiotics/prebiotics ameliorates inflammation state. In this work, we reviewed some nutritional interventions focusing on gut microbiota aimed at improving low-grade inflammation condition. Currently, 11 consumption of probiotics/prebiotics, polyphenols, or oligofructose/inulin counteracts gut dysbiosis and ameliorated inflammation state. Future advances on the knowledge of COVID-19 molecular mechanisms would lead to an improved understanding of interactions between SARS-CoV-2 and gut microbiota. In perspective, after microbiota analyses, a novel personalized nutritional approach will be developed to restore a healthy gut microbiota and avoid SARS-CoV-2-induced exacerbated inflammation in frail patients. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The binding of SARS-CoV-2 to ACE2 and its interaction with intracellular TLRs triggers a sequence of responses which leads to NF-bK activation and ILs synthesis. Host cell inflammation could be exacerbated by NLRP3 inflammasome activation and by proinflammatory cytokines production. NLRP3 inflammasome activation requires two steps generated by stressful conditions: the transcription of NLRP3 and ASC, pro-caspase-1 and their assembly and activation. The first step is consequent to NF-kB activation and translocation into the nucleus, stimulated by LPS-TLR4 binding through JNK and IKK intracellular signaling. The second step is induced by an abnormal mitochondrial ROS production, or by PAMPs, DAMPs and MAMPs stimuli related to gut dysbiosis. Moreover, the K + outflow, due to ATP extracellular stimulus, or intracellular and cytosolic Ca 2+ fluxes imbalance induces NLRP3 inflammasome assembly. NLRP3 activation is also regulated by AngII overexpression stimulated by LPS-TRL4 interaction and by gut dysbiosis-derived metabolite TMAO. COVID-19: a new challenge for human beings SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Pyroptotic cell death defends against intracellular pathogens Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K + efflux Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product Indirubin Inhibits LPS-Induced Inflammation via TLR4 Abrogation Mediated by the NF-kB and MAPK Signaling Pathways TLR4 Signaling Pathway Modulators as Potential Therapeutics in The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension Angiotensin II and the development of insulin resistance: implications for diabetes Relationships of decreased lung function with metabolic syndrome and obstructive sleep apnea in Japanese males Restrictive pulmonary deficit is associated with inflammation in sub-optimally controlled obese diabetics Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease Oxidative stress induced by prenatal LPS leads to endothelial dysfunction and renal haemodynamic changes through angiotensin II/NADPH oxidase pathway: Prevention by early treatment with α-tocopherol Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats Angiotensin II-induced hepatocyte EMT by inhibiting NOX-derived H2O2-activated NLRP3 inflammasome/IL-1β/Smad circuit Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts. Sci Rep. 2017 Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis Organ-protective effect of angiotensinconverting enzyme 2 and its effect on the prognosis of COVID-19 Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad Microbiome and diabetes: Where are we now? Gut Microbiota in Cardiovascular Health and Disease The Gut Microbiota and Healthy Aging: A Mini-Review Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals Gut dysbiosis is linked to hypertension Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy Gut Microbiota in Vascular Disease: Therapeutic Target? Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights into Atherosclerosis Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB Trimethylamine N-oxide activating ROS-TXNIP-NLRP3 inflammasome Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors Effect of lipopolysaccharide on inflammation and insulin action in human muscle The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance inflammasome as a potential treatment in ischemic stroke concomitant with diabetes Alveolar-Capillary Membrane-Related Pulmonary Cells as a Target in Endotoxin-Induced Acute Lung Injury Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury Analysis of Clinical Features of 29 Patients With 2019 Novel Coronavirus Pneumonia Microbiota regulates immune defense against respiratory tract influenza A virus 19 infection Commensal bacteria calibrate the activation threshold of innate antiviral immunity Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target Potential therapeutic role of L-carnitine in skeletal muscle oxidative stress and atrophy conditions Carnitine Reduces Oxidative Stress and Promotes Cells Differentiation and Bone Matrix Proteins Expression in Human Osteoblast-Like Cells An Antioxidant Remedy for the Survival of Cardiomyocytes under Hyperglycemic Condition Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model Enterobacter aerogenes ZDY01 Attenuates Choline-Induced Trimethylamine N-Oxide Levels by Remodeling Gut Microbiota in Mice Lactobacillus plantarum ZDY04 exhibits a strain-specific property of lowering TMAO via the modulation of gut microbiota in mice Gut Colonization with Methanogenic Archaea Lowers Plasma Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. mBio Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/-mice Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems. Front Microbiol Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats Dietary inulin alleviates diverse stages of type 2 diabetes mellitus via anti-inflammation and modulating gut microbiota in db/db mice Changes in nutrient absorption in children and adolescents caused by fructans, especially fructooligosaccharides and inulin Microbiota Composition and Function in Morbid Obese and Normal-Weight Subjects Oligofructose decreases serum lipopolysaccharide and plasminogen activator inhibitor-1 in adults with overweight/obesity Oligofructoseenriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors The effect of probiotics on inflammatory biomarkers: a metaanalysis of randomized clinical trials Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047 on high-fat and high-fructose diet mice base on inflammatory response alleviation and gut microbiota regulation Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease The Effect of Kyolic Aged Garlic Extract on Gut Inflammation, and Cardiovascular Markers in Hypertensives: The GarGIC Trial. Front Nutr Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Gut microbiota and Covid-19-possible link and implications Multimedica.